Deucravacitinib safer and more effective than apremilast for treating moderate to severe scalp psoriasis

A study has found that deucravacitinib is both safer and more effective than apremilast for treating moderate to severe scalp psoriasis. These findings suggest that deucravacitinib may be a promising treatment option for individuals with this condition. The study’s results provide valuable information for healthcare providers and patients seeking effective treatments for scalp psoriasis. This information is important for individuals managing this chronic condition and can help guide treatment decisions. Additionally, the study highlights the need for continued research and development of treatments for psoriasis to improve patient outcomes and quality of life.

Source link